Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction - PubMed
6 hours ago
- #Phosphodiesterase inhibitors
- #Autoimmune diseases
- #Immunomodulators
- Phosphodiesterase (PDE) inhibitors regulate immune and vascular function by controlling intracellular second messengers like cAMP and cGMP.
- PDE inhibitors impact vascular tone, immune cell activation, and fibrotic remodeling, relevant in autoimmune and neurodegenerative diseases.
- PDE3 inhibitors aid vasodilation and platelet regulation; PDE5 inhibitors enhance NO-cGMP signaling, used in pulmonary arterial hypertension.
- PDE4 inhibitors reduce pro-inflammatory mediators, benefiting conditions like psoriasis, psoriatic arthritis, and CTD-ILD.
- Emerging PDE-targeted agents like ibudilast and nerandomilast show promise in immunomodulation and antifibrotic therapy.
- Targeting NO-cGMP-cAMP signaling offers a unified approach for treating vascular, immune, and fibrotic aspects of rheumatic diseases.